TScan Therapeutics, a preclinical biotech developing engineered T cell cancer therapies, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
TScan Therapeutics is developing a pipeline of T cell receptor-engineered T cell, or TCR-T, therapies for the treatment of hematological and solid tumors. The company uses one of its propriety technology platforms, TargetScan, to analyze the T cells of cancer patients who have shown excellent responses to immunotherapy to inform the design of their TCR-T therapies. The company plans to submit INDs for its lead two liquid tumor candidates in the 4Q21 and at least three of its four solid tumor candidates in the 2H22.
The Waltham, MA-based company was founded in 2018 and plans to list on the Nasdaq under the symbol TCRX. TScan Therapeutics filed confidentially on March 19, 2021. Morgan Stanley, Jefferies, Cowen and Barclays are the joint bookrunners on the deal. No pricing terms were disclosed.
